This clinical trial is focused on studying the long-term safety and tolerability of a medication called Atogepant in children and teenagers aged 6 to 17 who experience Migraine. Migraines are severe headaches that can cause intense throbbing or pulsing in one area of the head, often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. The purpose of this study is to understand how safe and tolerable Atogepant is when used over a long period to prevent migraines in young people.

Participants in the study will take Atogepant in the form of a tablet, which is taken orally. The study will monitor participants for any side effects or adverse events, which are unexpected medical problems that occur during treatment. This includes regular checks on their health through laboratory tests, heart monitoring using an Electrocardiogram (ECG), and assessments of vital signs like blood pressure and heart rate. The study will also look at any changes in mood or behavior, especially any thoughts of self-harm, using a tool called the Columbia-Suicide Severity Rating Scale.

The study is designed to last for a significant period, allowing researchers to gather comprehensive data on the long-term effects of Atogepant. Participants will be closely monitored throughout the study to ensure their safety and well-being. This research aims to provide valuable insights into the use of Atogepant for preventing migraines in children and teenagers, potentially offering a new option for managing this challenging condition.